Jobs
-
According to an Insmed update, the company launched recently launched Arikayce amikacin liposome inhalation suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC) in Japan. The Japanese Ministry… Read more . . .
-
Berry Global has announced that it will construct a new facility in Bangalore, India that will serve as an R&D center and will add manufacturing capacity for devices, including nasal spray pumps and inhalers, to… Read more . . .
-
MannKind and NRx Pharmaceuticals will work together on a possible inhaled dry powder aviptadil based on MannKind’s Technosphere particle technology, the companies have announced. MannKind said that it would conduct the feasibility study at its… Read more . . .
-
According to Relief Therapeutics, the FDA has granted orphan drug designation for RLF-100 inhaled aviptadil for the treatment of sarcoidosis; RLF-100 is currently in Phase 2 development for that indication. Relief also recently acquired German… Read more . . .
-
Sanofi has agreed to pay approximately $3.2 billion for Translate Bio, which is developing inhaled mRNA therapies for cystic fibrosis, primary ciliary dyskinesia, and pulmonary arterial hypertension in addition to a number of intramuscular mRNA vaccines,… Read more . . .
-
Glenmark Pharmaceuticals has acquired the rights to manufacture and sell SaNOtize’s nitric oxide nasal spray (NONS) in India and at least a dozen other markets in Asia for the treatment of COVID-19, the companies have… Read more . . .
-
Satsuma Pharmaceuticals has initiated the SUMMIT Phase 3 trial of its STS101 dihydroergotamine (DHE) nasal powder for the treatment of migraine, the company said. A previous Phase 3 trial of STS101 called EMERGE failed to… Read more . . .
-
Submit workshop proposals by December 1, 2021 at https://www.rddonline.com/rdd/workshop_reg.php?id=21 Submit poster abstracts by January 21, 2022 at https://www.rddonline.com/rdd/poster_reg.php?id=21 Poster abstracts from graduate students that are accepted for the conference will automatically be entered into competition… Read more . . .
-
Augmenta Bioworks and TFF Pharmaceuticals have announced that in vitro testing of their AUG-3387 dry powder monoclonal antibody has demonstrated that the mAb neutralizes the SARS-CoV-2 Delta variant, the highly transmissible strain that is currently dominant in numerous… Read more . . .
-
According to Lannett, the company has acquired US rights to market Respirents generic of Spiriva Handihaler tiotropium bromide DPI for a 10-year period, the company said. Lannett had already acquired US rights to Respirent’s generic versions… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland